证券代码：603858 证券简称：步长制药 公告编号：2025-151 山东步长制药股份有限公司 关于拟转让控股子公司股权及放弃优先受让权的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、交易概述 济南步长财淦商贸有限公司（以下简称"步长财淦"）为山东步长制药股份 有限公司（以下简称"公司"）控股子公司，公司持有其 93.00%股权，房克瑞持 有其 4.00%股权，周彦丰持有其 3.00%股权。公司于 2025 年 5 月 19 日召开第五 届董事会第二十一次会议，审议通过了《关于公司拟转让控股子公司股权的议 案》，拟将持有的控股子公司步长财淦 1%股权转让给谢继辉。2025 年 7 月 11 日， 公司与谢继辉及有关各方分别签署了《关于济南步长财淦商贸有限公司之股权转 让协议》及《关于济南步长财淦商贸有限公司之合作协议书之补充协议》，截至 目前，上述协议涉及的股权变动尚未完成工商变更登记。具体内容详见公司 2025 年 7 月 12 日披露于上海证券交易所网站（www.sse.com.cn）的《关于拟转让控 股 ...

证券代码：603858 证券简称：步长制药 公告编号：2025-152 山东步长制药股份有限公司 关于控股子公司完成工商变更登记的公告 名称：杭州步长建鑫生物科技有限公司 类型：其他有限责任公司 法定代表人：易翠 注册资本：壹仟万元整 成立日期：2025 年 01 月 20 日 住所：浙江省杭州市萧山区盈丰街道时代博地大厦 5601 经营范围：一般项目：技术服务、技术开发、技术咨询、技术交流、技术转 让、技术推广；第一类医疗器械销售；第二类医疗器械销售；卫生用品和一次性 使用医疗用品销售；互联网销售（除销售需要许可的商品）；信息咨询服务（不 含许可类信息咨询服务）；广告设计、代理；广告发布；广告制作；医用口罩批 发；母婴生活护理（不含医疗服务）；国内贸易代理；保健食品（预包装）销售； 消毒剂销售（不含危险化学品）；个人卫生用品销售；化妆品零售；化妆品批发； 普通货物仓储服务（不含危险化学品等需许可审批的项目）；五金产品批发；五 1 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 山东步长制药股份有限公司（以下简称"公司"）于 ...

证券代码：603858 证券简称：步长制药 公告编号：2025-147 山东步长制药股份有限公司 第五届董事会第二十九次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 山东步长制药股份有限公司（以下简称"公司"）第五届董事会第二十九次 会议的通知于 2025 年 8 月 11 日发出，会议于 2025 年 8 月 15 日下午 13 时以通 讯方式召开，应参会董事 9 人，实参会董事 9 人，会议由董事长赵涛先生主持。 会议出席人数、召开和表决方式符合《中华人民共和国公司法》等法律、法规及 《山东步长制药股份有限公司章程》的相关规定，合法有效。 具体内容详见公司同日披露于上海证券交易所网站（www.sse.com.cn）的《关 于控股子公司山东丹红拟与山东中医药大学附属医院签署<技术转让（开发）合 同>的公告》（公告编号：2025-148）。 该议案已经公司董事会战略与投资委员会审议通过并同意提交董事会审议。 表决结果：同意 9 票，反对 0 票，弃权 0 票。 2、《关于控股子公司住所变更的议案》 公司控股子公 ...

人民财讯8月15日电，步长制药（603858）8月15日晚间公告，控股子公司山东丹红拟与山东中医药大学 附属医院就二至调经优化方阶段性成果转让及其新药开发事宜签署《技术转让(开发)合同》，山东中医 药大学附属医院将其拥有的中药二至调经优化方的技术所有权以总价1500万元转让予山东丹红。 双方将依据合同约定，开展中药新药研究，成功开发出用于治疗肾虚、肾气阴虚所致的卵巢储备功能减 退等适应症的中药1.1类新药，最终获得国家药品注册证书，并实现该新药的工业化规模生产。 ...

Group 1 - Company announced that its subsidiary, Shandong Danhong, plans to sign a technology transfer contract with Shandong University of Traditional Chinese Medicine Affiliated Hospital for 15 million RMB to acquire the ownership of a traditional Chinese medicine formula for new drug development [2] - The transaction does not constitute a related party transaction or a major asset restructuring and has been approved by the company's fifth board of directors at the 29th meeting, thus does not require shareholder approval [2]

Group 1 - The company, Buchang Pharmaceutical, announced that its subsidiary, Shandong Danhong, plans to sign a technology transfer (development) contract with Shandong University of Traditional Chinese Medicine Affiliated Hospital for a total price of 15 million RMB [1] - The contract involves the transfer of the technical ownership of a traditional Chinese medicine formula aimed at optimizing menstrual regulation, which is intended to enrich the product development pipeline [1] - The ultimate goal of this transaction is to achieve industrial-scale production of the new drug [1] Group 2 - This transaction does not constitute a related party transaction and does not qualify as a major asset restructuring [1]

Group 1 - Company has not yet launched mosquito repellent products and future product development will be announced through official company announcements [1]

Group 1 - The core viewpoint of the article is that the company, Bichang Pharmaceutical, is developing an injectable form of Epaipobatin α, which is a Class I new drug for therapeutic biological products, and currently, there are no similar products approved for sale in the domestic market [2] Group 2 - The company responded to investor inquiries regarding the competitive advantages of its injectable Epaipobatin α compared to existing similar drugs, emphasizing that it holds a unique position in the market due to the absence of comparable products [2]

Core Viewpoint - The company, Buchang Pharma, is demonstrating long-term confidence in its value by announcing the cancellation of repurchased shares, which reflects its commitment to shareholder returns and social responsibility [1][2]. Group 1: Share Repurchase and Cancellation - Buchang Pharma plans to cancel 51,474,203 repurchased shares, which accounts for 4.65% of the total shares before cancellation, reducing the total share capital from 1,106,042,645 to 1,054,568,442 shares [1]. - Since its listing, the company has conducted three share repurchases, totaling 87,012,200 shares and spending 1,744.43 million yuan, with 35,538,000 shares already canceled [2]. - The cancellation of shares is expected to enhance earnings per share and net asset value, stabilize stock prices, and reflect the company's financial health and cash flow [2]. Group 2: Financial Performance and Shareholder Returns - The company has approved a mid-term dividend plan for 2025, reinforcing its commitment to returning value to shareholders, with cumulative dividends exceeding 7.5 billion yuan since its establishment [2]. - Buchang Pharma has paid over 32 billion yuan in taxes and has contributed to local economic development through job creation [3]. Group 3: Industry Position and Product Development - With over 30 years in the traditional Chinese medicine sector, Buchang Pharma has developed a diversified portfolio across various pharmaceutical categories, becoming a leading innovator in traditional Chinese medicine [4]. - The company holds 468 valid patents and is advancing 213 research projects, focusing on major diseases and cultivating significant products [4]. - Recent international approvals for products like the "Stabilizing Heart Granules" in Malaysia and "Pulmonary Detox Granules" in Canada, Kazakhstan, and Uzbekistan indicate the company's global expansion efforts [5]. Group 4: Vision and Social Responsibility - Buchang Pharma aims to be "China's Johnson & Johnson, and the world's Buchang," emphasizing its commitment to social responsibility and innovation in the healthcare sector [5].

Group 1 - The company announced that its wholly-owned subsidiary, Baoding Tianhao Pharmaceutical Co., Ltd., received approval from the Hebei Provincial Drug Administration for changes in the production scope and entrusted production situation of its Drug Production License [1] - The production license includes various forms of medications such as ointments, tablets, solutions, and capsules, with the license valid until July 7, 2030 [1] - Changes in production lines include specific formulations such as "Oseltamivir Phosphate Oral Suspension" and "Donepezil Hydrochloride Tablets" [2][3] Group 2 - Baoding Tianhao Pharmaceutical Co., Ltd. has entrusted Shandong Buchang Pharmaceutical Co., Ltd. to produce Donepezil Hydrochloride Tablets, with the entrusted production valid until July 7, 2030 [3] - The changes in the Drug Production License are expected to optimize the production structure and maintain stable production capacity, positively impacting the company's future operations [4]